Passa al contenuto
Merck
  • S100A4 upregulation suppresses tissue ossification and enhances matrix degradation in experimental periodontitis models.

S100A4 upregulation suppresses tissue ossification and enhances matrix degradation in experimental periodontitis models.

Acta pharmacologica Sinica (2015-10-27)
Min Zhou, Zhuo-quan Li, Zuo-lin Wang
ABSTRACT

S100A4, also known as fibroblast-specific protein 1 or metastasin 1, is not only highly expressed in growth-stimulated cultured cells and metastatic tumor cells, but also in the periodontal ligament. The aim of this study was to investigate the roles of S100A4 in the pathogenesis of periodontitis and its regulatory mechanisms in inflammatory milieu. Experimental periodontitis was induced in rats by submarginal silk ligatures. TRAP activity and S100A4 expression in periodontal ligaments were examined using immunohistochemistry and immunofluorescence methods. IL-1β-treated human periodontal ligament cells (hPDLCs) were used as in vitro model of experimental periodontitis. S100A4 mRNA and protein were assessed using qRT-PCR and Western blot, respectively. hPDLCs were transfected with either S100A4 overexpression plasmids or shRNAs plasmids. The mineralization in hPDLCs was evaluated with a 12-d osteogenic induction assay, and the expression of ALP, OCN, MMP-2 and MMP-13 was analyzed by qRT-PCR. In the periodontal ligaments of rats with experimental periodontitis, TRAP activity and S100A4 protein staining were considerably more intense compared with those in the control rats. Treatment of hPDLCs with IL-1β (10, 50 and 100 ng/mL) dose-dependently increased the mRNA and protein levels of S100A4. Transfection with shRNAs markedly increased mineralized nodule formation and the osteogenic-related markers ALP and OCN levels in hPDLCs, whereas the overexpression of S100A4 significantly reduced mineralized nodule formation, and increased the matrix degradation enzymes MMP-2 and MMP-13 levels in hPDLCs. S100A4 is upregulated in the experimental rat periodontitis and in IL-1β-treated hPDLCs, where S100A4 suppresses osteogenic differentiation and enhances matrix degradation. Thus, S100A4 is a potential target for the treatment of periodontitis.

MATERIALI
Numero di prodotto
Marchio
Descrizione del prodotto

Sigma-Aldrich
Desametasone, powder, BioReagent, suitable for cell culture, ≥97%
Sigma-Aldrich
DAPI, for nucleic acid staining
Sigma-Aldrich
Acido L-ascorbico, powder, suitable for cell culture, γ-irradiated
Sigma-Aldrich
Fenil metansolfonile fluoruro, ≥98.5% (GC)
Sigma-Aldrich
Acido L-ascorbico, BioXtra, ≥99.0%, crystalline
Sigma-Aldrich
Acido L-ascorbico, suitable for cell culture, suitable for plant cell culture, ≥98%
Sigma-Aldrich
Acido L-ascorbico, 99%
Sigma-Aldrich
Acido L-ascorbico, reagent grade, crystalline
Sigma-Aldrich
Desametasone, ≥98% (HPLC), powder
Sigma-Aldrich
Fenil metansolfonile fluoruro, ≥99.0% (T)
Sigma-Aldrich
Acido L-ascorbico, ACS reagent, ≥99%
Supelco
Acido L-ascorbico, analytical standard
Sigma-Aldrich
Acido L-ascorbico, meets USP testing specifications
Sigma-Aldrich
Acido L-ascorbico, reagent grade
Sigma-Aldrich
Cetylpyridinium chloride, meets USP testing specifications
Sigma-Aldrich
Desametasone, powder, γ-irradiated, BioXtra, suitable for cell culture, ≥80% (HPLC)
Sigma-Aldrich
Acido L-ascorbico, puriss. p.a., ACS reagent, reag. ISO, Ph. Eur., 99.7-100.5% (oxidimetric)
Sigma-Aldrich
Acido L-ascorbico, FCC, FG
Sigma-Aldrich
Acido L-ascorbico, BioUltra, ≥99.5% (RT)
Sigma-Aldrich
Acido L-ascorbico, puriss. p.a., ≥99.0% (RT)
Sigma-Aldrich
Desametasone, meets USP testing specifications
Sigma-Aldrich
Edelfosine, ≥95% (HPLC)
Sigma-Aldrich
Ser-Phe-Leu-Leu-Arg-Asn-Pro-Asn-Asp-Lys-Tyr-Glu-Pro-Phe, ≥97% (HPLC)